Vigabatrin (GVG) and lamotrigine (LTG) are new antiepileptic drugs (AEDs) individually et~ective as add-on therapy for refractory seizures. The efficacy of GVG and LTG in combination was evaluated in a prospective audit of 42 patients with intractable epilepsy. There was a statistically significant median reduction of 62% (P < 0.025) from a median baseline monthly seizure frequency (MSF) of 29 (mean 59, 95% CI 22, 96) to a median MSF of 11 (mean 23, 95% CI 8, 38) during a median treatment period of eight months, with a greater than 50% reduction in MSF in 29 patients (69%) treated with the add-on combination of GVG and LTG. The additional MSF reduction achieved by the combination amounted to 21% (18% when GVG was added to LTG and 24% when LTG was added to GVG). The median trough plasma lamotrigine concentration was 9.9 mg/I (range 3.4-19.6 mg/I). The average daily dose of LTG was 517 mg (range, 175-800 mg) and GVG 2400 mg (range, 1500-3500 mg). Adverse events requiring alteration of therapy occurred in 24 patients (57%) with a drop-out rate of 12%. The combination of GVG and LTG should be considered as a therapeutic option in patients with intractable epilepsy. The results of the present study support the need to confirm additive antiepileptic efficacy of GVG and LTG by conducting controlled trials of this combination therapy.
INTRODUCTION
One in five patients with newly diagnosed epilepsy develop complex partial seizures which cannot be controlled by conventional AEDs and may be considered for temporal lobectomy t. Patients with the Lennox-Gastaut syndrome (LGS) are often so handicapped by medically refractory tonic and atonic seizures that the operation of section of the corpus callosum may be performed as a palliative procedure 2. GVG and LTG are newly developed AEDs, each of which has been shown to be effective in controlled trials of add-on therapy in patients with refractory partial seizures 3. LTG may be particularly effective against secondarily generalized and tonic seizures 4"5. GVG appears to be most effective in controlling complex partial seizures 6 .
From December 1990 to April 1991 LTG was added to GVG and the conventional AEDS of four patients who had a long-standing history of refractory complex partial and tonic seizures. This was done because of limited antiepileptic response in these patients to single add-on therapy with either GVG or LTG, taking into account the pharmacological potential of novel AEDS, such as LTG and GVG, to have additive efficacy. There was also a report from the UK of apparent improvement in seizure control following the combination of GVG and LTG 7. Improvement in seizure control was observed in these four patients over the ensuing six months when the LTG dose was stepped up to achieve a trough plasma level between 5 and 15mg/1 without intolerable side-effects. The aim of the present study was to determine whether GVG and LTG in combination would be consistently effective for treating a larger number of patients with intrac- 
Epilepsies and seizures
Localization-related epilepsy (LRE)-was diagnosed in 32 patients, cryptogenic/symptomatic generalized epilepsy (CGSE) in five patients--who satisfied the diagnostic criteria for LennoxGastaut syndrome (LGS)2--and undetermined focal or generalized epilepsy (UFGE) in five patients.
Complex partial seizures were the most common seizure type (Table 1) , and there was more than one seizure type in 41 patients ( Table 2) . The most common seizure combination in any individual patient was that of simple partial, complex partial and secondarily generalized tonic-clonic seizures in 15 patients, each of the five patients with CGSE (LGS) had aggregations of three to six (average four) different seizure types (Table 3) .
Seizures were recorded in a day to day seizure diary by the patient or care-giver, and were coded for seizure type. MSF was the mean seizure number over 28 days, calculated from the total number of seizures in the last three therapeutically stable consecutive periods of 28 days. Antiepileptic response was expressed as the elevate the plasma LTG level in advance of progressive withdrawal of enzyme inducing AEDs. In 15 patients PHT was associated with depressed plasma LTG level relative to dose, with an elimination plasma half-life of four hours in one patient. Combination GVG and LTG the rapy was established with reduction of conven tional AEDs during hospitalization in half the patients and in an outpatient environment in the other half.
Antiepileptic drugs
The average number of conventional AEDs per patient was two (range, one to four) as shown in Table 4 .
ADVERSE EVENTS
Regular clinical assessment and monitoring of full blood count, routine plasma biochemistry, urin alysis and microurine were carried out through out the study. EEGs were performed on all patients as part of their diagnostic epilepsy management and neuropsychological cognitive assessment, psychiatric evaluation and dermatological consultations were obtained at appropriate intervals or when indicated.
PLASMA LAMOTRIGINE LEVEL
The plasma LTG therapeutic window in phase III was estimated as follows. Trough plasma LTG levels were analysed in 28 patients, on samples collected when their median MSF fell by 50% or more in phase III, compared with phase I. The plasma LTG levels were also analysed in 16 patients when they developed adverse events which were circumstantially related to an increase (Fig. 1) . The reduction in median MSF from phases I to II did not achieve statistical significance, but the reductions from II to III and I to III achieved significance at P<0.05 and P < 0.025, respectively. Table 6 shows the seizure frequencies and percentage seizure decreases during phases I, II and III for the three different epilepsy groups. The two groups with generalized epilepsy had almost three times the seizure frequency of the localization-related group in phase I. The seizure response varied in phase III according to epilepsy syndrome ( Table 6 ). The percentage reduction in seizure frequency from phase II to phase III was comparable whether LTG was added to GVG in the majority of 27 patients (38 and 62%, respectively) or GVG was added to LTG in the minority of 15 patients (42 and 60%, respectively). Thus the sequence of addition of the second new drug did not appear to produce any difference in seizure reduction from phase II to phase III (Table 5) . Adverse events were experienced in phase III by 24 patients (57%) and are listed in Table 7 . The most clinically significant adverse events involved disturbances of higher cerebral function attributable to GVG, including aggressive behaviour (12 patients), psychomotor retardation (eight patients), delusions (eight patients), impaired memory (seven patients) and depression (seven patients). Aggressive personality change required discontinuation of GVG in three patients. Dose-related adverse events, attributable to LTG, included ataxia (15 patients), diplopia (ten patients), headache (eight patients) and vomiting (eight patients), which usually responded to dose reduction. Skin rash was circumstantially related to LTG in 11 patients (26%), appearing on average ten days after the commencement of the drug. It was usually a pruritic, papular rash on the trunk and upper extremities and remitted in all but one patient while the drug was continued. However in one patient the rash was acneform, did not abate and was the reason why LTG was finally withdrawn. Seizure clustering, a marked (often several-fold) increase in seizure frequency over a relatively short period of time (e.g. 24-48 hours) was viewed as an adverse event in ten patients. It frequently resulted in admission to hospital because of recurrence of atypical absenses (recurrent blank stares for an hour or more) and at times required short-term benzodiazepine (diazepam, clonazepam or clobazam) therapy. Increased appetite and excessive weight gain were noted in three patients in phase III (Table 7 ). There was a 12% drop-out rate (five patients) due to adverse events in phase III. LTG was discontinued in one patient because of pancytopenia, which recurred on re-challenge, and her GVG was also withdrawn because of aggressive personality change and delusions. LTG was withdrawn in another patient because of skin rash. GVG was discontinued in 2 other patients because of psychomotor retardation and possible deterioration in seizure control with clustering. The fifth patient died suddenly in phase III when he fell from a building, possibly intentionally. The median trough plasma LTG level in the total population of 42 patients in phase III was 9.9mg/l (range, 3.4-19.6mg/1). The median trough plasma LTG level at which the MSF fell by at least 50% in the responders was 7.9mg/l (range, 2.1-15.4 mg/l). The median plasma LTG level at which LTG dose-related side-effects, including ataxia, diplopia, dysarthria, headache and vomiting, appeared in phase III was 16.0 rag/1 (range, 7.9-19.4mg/1). Thus a plasma LTG therapeutic window of 7.9-16.0mg/1 was indicated in phase III when patients were taking LTG in combination with GVG. Two patients exhibited LTG dose-related ataxia associated with disparate trough and post-dose plasma LTG values, in one patient 15.4 and 21.7 mg/l and in another 8.1 and 28.1 mg/l, respectively.
DISCUSSION
Conventional two-drug therapy is stated to be clearly effective in treating one in five patients with partial or tonic-clonic seizures who do not respond to monotherapy 9. The addition of LTG to GVG has been reported to result in considerable improvement in the seizure response rate of three patients with intractable secondary generalization of epilepsy which had failed to respond to temporal lobectomy 7. Recently placebo-controlled addition of LTG to an AED regimen containing GVG resulted in a significant (37%) reduction in partial seizures, with nine of 22 patients with refractory epilepsy reporting more than a 50% reduction by a maximal daily LTG dose of 200 mg and median plasma level of 2.4 mg/l 1°. In the present study of patients with intractable epilepsy there was an additional 21% (overall 61%) improvement in seizure control, with a 50% or better improvement in seizure control in over two-thirds (69%) of 42 patients when LTG and GVG were combined with conventional AEDS, provided the trough plasma LTG level could be tolerated above 8mg/l. Sodium valproate (VPA) enabled this to be achieved in 40% of patients, presumably by inhibiting LTG metabolism which had been enhanced by auto-induction or induction by conventional AEDS such as phenytoin (PHT) 4. The therapeutic plasma concentration window for LTG in combination with GVG as add-on antiepileptic therapy was 7.9-16 mg/l. This proposed therapeutic range is significantly higher than that (1.5-3 mg/l) previously proposed 11 and that (1-7.9 mg/l) found in a recent placebo-controlled study j°. It reflects both a higher total daily dose of LTG and the frequent concomitant administration of VPA, which appeared to be necessary to provide optimal seizure control in this population of patients with severe epilepsy.
One cannot exclude the possibility that VPA added pharmacodynamic anti-seizure efficacy to the other AEDs in the 30 patients taking it in phase III, as reported in a patient with refractory generalized myoclonic epilepsy ~2. Another explanation for the unexpected improvement in seizure control might be the superior efficacy of VPA, GVG or LTG as monotherapy, particularly considering the relatively high plasma LTG levels achieved in the present study. This was not tested by consistently attempting to withdraw LTG or GVG in responders. Discontinuation of VPA was subsequently achieved in the face of compensatory increases in LTG dosage to maintain plasma LTG levels in half the valproate treated patients without obvious loss of seizure control. One cannot also exclude the possibility that discontinuation of baseline, conventional AEDs in 34 patients during phase III altered seizure control. An attempt was made to minimize this possibility by introducing and increasing the investigational drugs (LTG and GVG) after adequate periods of therapeutic stability prior to decreasing conventional drugs and by making only one therapeutic change at any one time. Non-compliance may have boen a factor in a few patients whose seizure control did not improve. However, plasma antiepileptic drug concentrations were generally consistent with dosage in most patients, whose motivation was probably relatively high in this selected population characterized by severe epiepsy and previous drug trial experience. Noncompliance was therefore considered unlikely in the majority of these patients.
The side-effect profile observed with this add-on combination of LTG and GVG was qualitatively comparable to that seen with conventional AEDs and similar to that reported for each new drug when administered as single add-on therapy 3'5, but the frequency of events was relatively high, with 57% of patients exhibiting a range of effects, including mild transient rash, headache, vomiting, occasional pancytopenia and more dramatic behavioural disturbances, which were all reversible on drug withdrawal and resulted in a drop-out rate of only 12%. Offsetting this was the magnitude of the therapeutic benefit in a patient population with severe, intractable elipeptic syndromes, indicating the need for further, controlled trials of this combination of novel AEDs to establish its value
